Tenecteplase
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Tenecteplase |
| DrugBank ID | DB00031 |
| Brand Names (EU) | Metalyse |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.91% |
Approved Indication (EMA)
Metalyse is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left-bundle-branch block within six hours after the onset of acute-myocardial-infarction symptoms. Metalyse is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | myocardial infarction | 99.91% | DL |
| 2 | posteroinferior myocardial infarction | 99.87% | DL |
| 3 | posterolateral myocardial infarction | 99.87% | DL |
| 4 | septal myocardial infarction | 99.85% | DL |
| 5 | coronary thrombosis | 99.80% | DL |
| 6 | hemoglobinopathy | 99.69% | DL |
| 7 | congenital coronary artery anomaly | 99.61% | DL |
| 8 | coronary stenosis | 99.53% | DL |
| 9 | myocardial infarction (disease) | 99.49% | DL |
| 10 | partial deletion of the short arm of chromosome 16 | 99.34% | DL |
| 11 | beta-thalassemia with other manifestations | 99.29% | DL |
| 12 | hemolytic anemia due to glucophosphate isomerase deficiency | 99.26% | DL |
| 13 | pyropoikilocytosis, hereditary | 99.20% | DL |
| 14 | pyruvate kinase deficiency of red cells | 99.20% | DL |
| 15 | heparin cofactor 2 deficiency | 96.66% | DL |
| 16 | antithrombin deficiency type 2 | 95.48% | DL |
| 17 | factor 5 excess with spontaneous thrombosis | 95.33% | DL |
| 18 | thrombophilia | 94.76% | DL |
| 19 | pulmonary embolism (disease) | 91.10% | DL |
| 20 | acute coronary syndrome | 87.44% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.